Alpine Immune Sciences Inc.

9.29-0.1900-2.00%Vol 111.86K1Y Perf 127.16%
Jun 15th, 2021 16:00 DELAYED
BID9.29 ASK9.32
Open9.71 Previous Close9.48
Pre-Market- After-Market-
 - -  - -%
Target Price
21.40 
Analyst Rating
Strong Buy 1.00
Potential %
130.36 
Finscreener Ranking
★★★     50.39
Insiders Trans % 3/6/12 mo.
-/-100/-60 
Value Ranking
     42.21
Insiders Value % 3/6/12 mo.
-/-100/-98 
Growth Ranking
★★★+     57.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-97 
Income Ranking
 —    -
Market Cap222.17M 
Earnings Rating
Sell
Price Range Ratio 52W %
42.67 
Earnings Date
13th May 2021

Today's Price Range

9.139.98

52W Range

4.0216.37

5 Year PE Ratio Range

-1.10-1.80

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
1.42%
1 Month
-21.47%
3 Months
-29.78%
6 Months
-32.53%
1 Year
127.16%
3 Years
8.02%
5 Years
-40.90%
10 Years
-

TickerPriceChg.Chg.%
ALPN9.29-0.1900-2.00
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.30
0.25
0.42
-36.90
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
-
-281.10
-275.80
-2 206.10
-
RevenueValueIndustryS&P 500US Markets
11.45M
0.48
151.35
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.32-0.45-40.62
Q04 2020-0.27-0.270.00
Q03 2020-0.23-0.28-21.74
Q02 2020-0.23-0.53-130.43
Q01 2020-0.48-0.3037.50
Q04 2019-0.55-0.3340.00
Q03 2019-0.67-0.627.46
Q02 2019-0.65-0.641.54
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.290.00-
9/2021 QR-0.35-20.69Negative
12/2021 FY-1.30-91.18Negative
12/2022 FY-1.11-63.24Negative
Next Report Date-
Estimated EPS Next Report-0.32
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume111.86K
Shares Outstanding23.92M
Trades Count2.07K
Dollar Volume815.47K
Avg. Volume121.76K
Avg. Weekly Volume161.21K
Avg. Monthly Volume160.25K
Avg. Quarterly Volume106.95K

Alpine Immune Sciences Inc. (NASDAQ: ALPN) stock closed at 9.29 per share at the end of the most recent trading day (a -2% change compared to the prior day closing price) with a volume of 111.86K shares and market capitalization of 222.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Alpine Immune Sciences Inc. CEO is Mitchell H. Gold.

The one-year performance of Alpine Immune Sciences Inc. stock is 127.16%, while year-to-date (YTD) performance is -26.27%. ALPN stock has a five-year performance of -40.9%. Its 52-week range is between 4.02 and 16.37, which gives ALPN stock a 52-week price range ratio of 42.67%

Alpine Immune Sciences Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 3.95, a price-to-sale (PS) ratio of 18.40, a price to cashflow ratio of 8.20, a PEG ratio of 2.32, a ROA of -36.12%, a ROC of -52.89% and a ROE of -82.90%. The company’s profit margin is -%, its EBITDA margin is -275.80%, and its revenue ttm is $11.45 Million , which makes it $0.48 revenue per share.

Of the last four earnings reports from Alpine Immune Sciences Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Alpine Immune Sciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Alpine Immune Sciences Inc. is Strong Buy (1), with a target price of $21.4, which is +130.36% compared to the current price. The earnings rating for Alpine Immune Sciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alpine Immune Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alpine Immune Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.81, ATR14 : 0.75, CCI20 : -59.99, Chaikin Money Flow : -0.16, MACD : -0.76, Money Flow Index : 20.00, ROC : -9.01, RSI : 39.88, STOCH (14,3) : 24.15, STOCH RSI : 0.82, UO : 39.43, Williams %R : -75.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alpine Immune Sciences Inc. in the last 12-months were: Mitchell H. Gold (Sold 20 000 shares of value $246 046 ), Peter A. Thompson (Sold 600 000 shares of value $8 550 000 ), Robert E. Conway (Buy at a value of $80 300)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Alpine Immune Sciences Inc.

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.

CEO: Mitchell H. Gold

Telephone: +1 206 788-4545

Address: 188 East Blaine Street, Seattle 98102, WA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

66%34%

Bearish Bullish

54%46%

News

Stocktwits